Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company dedicated to the treatment and prevention of cancer. The company's core focus includes developing vaccines and therapies aimed at critical unmet needs in oncology. Anixa's innovative approach involves both diagnostics and therapeutics to detect and treat cancer at its most curable stages.
The company's therapeutic portfolio features a pioneering ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center. This program utilizes a novel CAR-T technology, known as chimeric endocrine receptor T-cell (CER-T), which targets the follicle-stimulating hormone receptor (FSHR) specifically expressed on ovarian cells. This technology represents a potential breakthrough in treating solid tumors, a challenge for traditional CAR-T therapies.
Anixa is also advancing a unique vaccine portfolio in collaboration with Cleveland Clinic, targeting the prevention of breast cancer, specifically triple-negative breast cancer (TNBC), the most aggressive form of the disease, as well as ovarian cancer. These vaccine technologies focus on immunizing against
Anixa Biosciences (NASDAQ: ANIX) announced a presentation regarding its ongoing breast cancer vaccine trial at the 2022 San Antonio Breast Cancer Symposium on December 7, 2022. The presentation, titled Phase I trial of an alpha-lactalbumin vaccine in patients with operable triple-negative breast cancer (TNBC), highlights the trial's design and aims to activate the immune response against a protein expressed in most TNBC cases. Anixa emphasizes its innovative approach in cancer immunotherapy, focusing on prevention through its vaccine technologies.
On October 31, 2022, Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Jose Conejo-Garcia, the inventor of its ovarian cancer CAR-T technology, will be the keynote speaker at Duke Cancer Institute's Immuno-Oncology Research Program Retreat on November 4, 2022. Dr. Conejo-Garcia will present on the CAR-T technology, which targets the follicle stimulating hormone receptor (FSHR) in ovarian cancer and is undergoing a Phase 1 clinical trial. This innovative approach is part of Anixa's broader mission to develop cutting-edge therapies for cancer and infectious diseases.
Anixa Biosciences, Inc. (NASDAQ: ANIX) has initiated a Phase 1b trial for its preventive breast cancer vaccine at Cleveland Clinic, focusing on safety and immune response. The study, funded by the U.S. Department of Defense, is recruiting high-risk cancer-free participants who will receive three vaccinations over six weeks. This follows a Phase 1a trial with promising results, encouraging the company to advance earlier than planned. The trial aims to tackle triple-negative breast cancer, known for its lethality, with completion expected by the end of 2023.
Anixa Biosciences (NASDAQ: ANIX) announced a presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting on its ovarian cancer CAR-T therapy trial. Scheduled for November 10, 2022, at 9:00 AM EST, the presentation will be led by Dr. Robert Wenham from Moffitt Cancer Center. The trial focuses on genetically engineered T-cells targeting the follicle-stimulating hormone receptor in recurrent ovarian cancer patients. Anixa is advancing various therapeutic programs, including collaborations for COVID-19 and breast cancer vaccines.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced Dr. Jose Conejo-Garcia will present at the Rivkin Center and the American Association for Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium on September 28, 2022. He will discuss the company's ovarian cancer CAR-T technology, targeting follicle-stimulating hormone receptors on ovarian granulosa cells. The ongoing Phase 1 clinical trial has successfully treated its first patient, potentially transforming ovarian cancer treatment. Anixa collaborates with Moffitt Cancer Center on this innovative approach.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. This hybrid event will include a presentation detailing Anixa's recent corporate achievements, including the treatment of the first patient in its CAR-T based ovarian cancer clinical trial. The on-demand presentation will begin at 7:00 a.m. ET on September 12, 2022, with a replay accessible for 90 days. Anixa focuses on cancer and infectious disease therapies and collaborates with top research institutions.
Anixa Biosciences, Inc. (NASDAQ: ANIX) has initiated treatment for the first patient in a Phase 1 clinical trial of its chimeric antigen receptor T-cell (CAR-T) therapy aimed at ovarian cancer, in partnership with Moffitt Cancer Center. The trial will assess the safety and efficacy of the therapy targeting the follicle stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells. A total of up to 48 patients will participate in the study, with hopes that the unique targeting approach can enhance treatment effectiveness for challenging solid tumors.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced a Notice of Allowance from the U.S. Patent and Trademark Office regarding its breast cancer vaccine technology. This notice broadens intellectual property protection for the vaccine, which aims to prevent Triple Negative Breast Cancer (TNBC). Developed in collaboration with Cleveland Clinic, the vaccine is currently in Phase 1 clinical trials, with preliminary results expected by year-end. The technology leverages a breast-specific protein, α-lactalbumin, to stimulate immune protection against certain breast tumors.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced the publication of a peer-reviewed article in Clinical and Experimental Vaccine Research, detailing preclinical studies on a novel ovarian cancer vaccine technology using AddaVax adjuvant. The study indicates that the vaccine targets the anti-Müllerian hormone receptor 2, potentially preventing ovarian cancer—a challenging malignancy. Anixa's CEO stated that clinical development is ongoing, backed by the National Cancer Institute's PREVENT Program. This technology represents a significant advancement in cancer prevention.
Anixa Biosciences, Inc. (NASDAQ: ANIX) will present a company update at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will cover Anixa's recent achievements, including the initiation of a clinical trial for its CAR-T based ovarian cancer treatment. The on-demand presentation starts at 7:00 a.m. ET on May 24, 2022, and can be accessed through a provided webcast link. A replay will be available for 90 days. Anixa focuses on cancer therapies and infectious diseases, collaborating with top medical institutions to develop innovative treatments.
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
What does Anixa Biosciences specialize in?
What are the key components of Anixa's therapeutic portfolio?
What recent achievements has Anixa Biosciences announced?
Who are some of Anixa Biosciences' key collaborators?
How does Anixa's CER-T technology differ from traditional CAR-T therapies?
What is unique about Anixa's cancer vaccine technology?
Which forms of cancer are Anixa's vaccines targeting?
What are some recent clinical trial results from Anixa?
Does Anixa Biosciences participate in industry conferences?
Where can I find more information about Anixa Biosciences?
